Sinopharm Group Co. Ltd. (1099.HK)
- Previous Close
21.750 - Open
21.750 - Bid 21.550 x --
- Ask 21.600 x --
- Day's Range
21.350 - 22.150 - 52 Week Range
17.440 - 28.450 - Volume
8,013,009 - Avg. Volume
5,115,635 - Market Cap (intraday)
67.25B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
6.86 - EPS (TTM)
3.140 - Earnings Date Apr 26, 2024
- Forward Dividend & Yield 0.94 (4.33%)
- Ex-Dividend Date Jun 17, 2024
- 1y Target Est
27.58
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
www.sinopharmgroup.com.cn115,959
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1099.HK
Performance Overview: 1099.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1099.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1099.HK
Valuation Measures
Market Cap
67.87B
Enterprise Value
78.66B
Trailing P/E
6.94
Forward P/E
6.62
PEG Ratio (5yr expected)
2.48
Price/Sales (ttm)
0.11
Price/Book (mrq)
0.84
Enterprise Value/Revenue
0.13
Enterprise Value/EBITDA
3.50
Financial Highlights
Profitability and Income Statement
Profit Margin
1.52%
Return on Assets (ttm)
3.73%
Return on Equity (ttm)
13.03%
Revenue (ttm)
596.57B
Net Income Avi to Common (ttm)
9.05B
Diluted EPS (ttm)
3.140
Balance Sheet and Cash Flow
Total Cash (mrq)
63.81B
Total Debt/Equity (mrq)
61.32%
Levered Free Cash Flow (ttm)
6.64B
Research Analysis: 1099.HK
Company Insights: 1099.HK
1099.HK does not have Company Insights